Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
暂无分享,去创建一个
S. Yamashita | H. Daida | H. Arai | S. Ishibashi | M. Harada‐Shiba | S. Oikawa | H. Bujo | D. Masuda | N. Koga | Daisaku Masuda
[1] T. Okamura,et al. Defining patients at extremely high risk for coronary artery disease in heterozygous familial hypercholesterolemia. , 2012, Journal of atherosclerosis and thrombosis.
[2] W. Xia,et al. Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis , 2016, Expert opinion on pharmacotherapy.
[3] G. Corrao,et al. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. , 2017, Atherosclerosis.
[4] M. Kawashiri,et al. Targeted Panel Sequencing will Boost Detection of Genetic Backgrounds of Familial Hypercholesterolemia in the World's Most Populous Country , 2020, Journal of atherosclerosis and thrombosis.
[5] T. Funahashi,et al. Effects of probucol on xanthomata regression in familial hypercholesterolemia. , 1986, The American journal of cardiology.
[6] V. Vaccarino,et al. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. , 1989, Arteriosclerosis.
[7] Yasuo Ohashi,et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.
[8] S. Yamashita,et al. Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the research committee of the ministry of health, labour and welfare of Japan. , 2004, Journal of atherosclerosis and thrombosis.
[9] T. Farag. Familial hypercholesterolemia. , 1988, Journal of the Royal Society of Medicine.
[10] H. Mabuchi,et al. Development of coronary heart disease in familial hypercholesterolemia. , 1989, Circulation.
[11] Zhou Zhou,et al. Targeted Genetic Analysis in a Chinese Cohort of 208 Patients Related to Familial Hypercholesterolemia , 2020, Journal of atherosclerosis and thrombosis.
[12] P. Amarenco,et al. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention , 2009, The Lancet Neurology.
[13] J. Danesh,et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. , 2016, Journal of the American College of Cardiology.
[14] S. Yamagishi,et al. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. , 2006, Medical hypotheses.
[15] Ian Graham,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.
[16] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[17] H. Daida,et al. Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemia-Ezetimibe Phase IV Randomized Controlled Trial in Patients With Hypercholesterolemia. , 2012, Current therapeutic research, clinical and experimental.
[18] M. Vavlukis,et al. Adding ezetimibe to statin therapy: latest evidence and clinical implications , 2018, Drugs in context.
[19] G. Watts,et al. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. , 2012, The Journal of clinical endocrinology and metabolism.
[20] S. Yamashita,et al. Guidelines for the management of familial hypercholesterolemia. , 2012, Journal of atherosclerosis and thrombosis.
[21] S. Yamashita,et al. Probucol Enhances the Expression of Human Hepatic Scavenger Receptor Class B Type I, Possibly Through a Species-Specific Mechanism , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[22] K. Matsuki,et al. Familial Hypercholesterolemia and Lipoprotein Apheresis , 2019, Journal of atherosclerosis and thrombosis.
[23] Carolyn M Hutter,et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. , 2004, American journal of epidemiology.
[24] Jennifer G. Robinson,et al. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.
[25] S. Yokoyama,et al. Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. , 2010, Journal of atherosclerosis and thrombosis.
[26] S. Kihara,et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017 , 2018, Journal of atherosclerosis and thrombosis.
[27] A. Hirayama,et al. Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study. , 2018, Atherosclerosis.
[28] M. Harada‐Shiba,et al. Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[29] D. Illingworth,et al. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. , 1989, Arteriosclerosis.
[30] S. Yamashita,et al. Did we abandon probucol too soon? , 2015, Current opinion in lipidology.
[31] C. Farley,et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663 , 2000, British journal of pharmacology.
[32] D. Tribble,et al. Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans , 2002, Circulation.
[33] Jonathan C. Cohen,et al. Autosomal Recessive Hypercholesterolemia Caused by Mutations in a Putative LDL Receptor Adaptor Protein , 2001, Science.
[34] S. Yamashita,et al. Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE) , 2020, Journal of atherosclerosis and thrombosis.
[35] L. Räber,et al. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. , 2015, European heart journal.
[36] Barry J. Davis,et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.
[37] S. Yamashita,et al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. , 2008, Journal of atherosclerosis and thrombosis.